Masters announces £2.7 million investment and Burns appointment
This article was originally published in Scrip
Executive Summary
Masters Pharmaceuticals, a UK-based healthcare solutions provider specialising in named patient/expanded access programmes for discontinued products, orphan drugs and medicines in clinical development, has secured a £2.65 million investment from venture capitalists Albion Ventures.